



CLINICAL GUIDELINE

Dexamethasone Intravitreal Implant for the treatment of Retinal Vein Occlusion

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Version Number:	5
Does this version include changes to clinical advice:	No
Date Approved:	12 th March 2025
Date of Next Review:	31 st March 2028
Lead Author:	Michael P Gavin
Approval Group:	Medicines Utilisation Subcommittee of ADTC

Important Note:

The online version of this document is the only version that is maintained. Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.

Dexamethasone Intravitreal Implant for the treatment of Retinal Vein Occlusion

Patient Eligibility

Inclusion criteria

- Patients with decreased visual acuity as a result of clinically detectable macular oedema associated with either 1. central retinal vein occlusion (CRVO) or 2. branch retinal vein occlusion (BRVO) who are not clinically suitable for laser treatment including patients with dense macular haemorrhage or patients who have received and failed on previous laser treatment
- Eligible patients will have best-corrected visual acuity of 6/12 or worse in the treated eye due to macular oedema in the doctor's opinion.
- Retinal thickness in the central subfield (as measured by optical coherence tomography) has to be greater than 300 µm in the eye to be treated or there must be fovea-involving oedema reducing vision.

Exclusion criteria

- Spontaneous improvement of vision of 10 letters or more from time of listing to point of injection – consider withholding therapy
- Consider laser in BRVO as first line (SMC guidance) and use dexamethasone implant (Ozurdex®) for non-responders
- the presence of a clinically significant epiretinal membrane, macular ischaemia, active retinal or optic disc neovascularisation (relative contraindications) consider alternative interventions
- presence of rubeosis iridis (relative contraindication – treat rubeosis first with PRP +/- anti-VEGF)
- any active infection
- aphakia or anterior-chamber intraocular lens (relative contraindication)
- glaucoma or current ocular hypertension requiring more than 1 medication to control IOP in the eye to be treated, or a history of steroid-induced IOP increase in either eye (relative contraindication)
- administration to both eyes concurrently
- Hypersensitivity to the active substance or to any of the excipients as listed in the product literature (SPC)

Injection Technique

A topical disinfectant such as povidone-iodine should be applied to the conjunctival fornix

Following topical anaesthesia (below) as well as applied to the periocular skin including the eyelids and left in contact with the skin for 3 minutes before an eyelid drape and speculum are then applied.

Use local anaesthesia – either topical Proxymetacaine and/ or Oxybuprocaine and consider additional subconjunctival local anaesthetic eg. Lidocaine 1% at the injection site.

Whilst the injection is usually administered in a suitable clean room, following the local SOP, consideration can also be given to using an operating theatre with an appropriate operating microscope until the doctor administering the drug is more comfortable with the injection technique or if a clean room facility is unavailable.

Monitoring

Follow up and Investigate patient according to Royal College of Ophthalmologists published guidelines on the management of retinal vein occlusion (see website for details)

Patients will be reviewed within 4 weeks of dexamethasone implant (Ozurdex®) injection, at 2 months and then on a 2 monthly basis to the 6 month point and then 3 monthly until stable. Retreatments may be given at approximately 6 months from initial treatment or after 4 months if the clinician considers appropriate.

Criteria for retreatment: (Any one or combination of the following)

1. loss of BCVA of >5 letters from best achieved
2. OCT thickness >300µm or persistent oedema involving the fovea
3. Increase in OCT thickness of >50 µm from thinnest measurement.

Criteria for no further treatments:

1. Development of ischaemia and/or neovascularisation requiring laser therapy
2. Development of a significant steroid response (>35mmHg on more than one IOP lowering medication).
3. Patients who experience a deterioration in vision, which is not slowed by dexamethasone implant (Ozurdex®), should not be retreated